Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
Posted: 1 June 2023 Firebrick Pharma is pleased to provide an update on the progress of the confirmatory Phase 3 clinical trial of Nasodine Nasal Spray as a treatment for the common cold. The study, which commences in…
Optiscan Launches Entitlement Offer to Raise $16.7M
Posted: 1 June 2023 Optiscan Imaging Limited (ASX: OIL) is pleased to announce that it has lodged a prospectus with ASIC (Prospectus) in respect of a pro rata entitlement offer of one (1) fully paid ordinary share (Share)…
Incisive Technologies announces the US FDA has issued 510K clearance for BlueCheck Caries Detection and Monitoring
Posted: 30 May 2023 Incisive Technologies announces the US Food and Drug Administration (FDA) has issued 510K clearance for BlueCheck™ Caries Detection and Monitoring, a novel caries detection device used by clinicians in dental examinations to aid the…
4DMedical completes oversubscribed $25m Securities Purchase Plan
Posted: 30 May 2023 Respiratory imaging technology company, 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) is pleased to announce the successful completion of its SPP. Strong support was received from 1,129 Eligible Shareholders, out of a total of…
Stellar scientists join the Australian Academy of Science
Posted: 30 May 2023 Professor Sharon Lewin AO and Professor Andrew Wilks have been elected as 2023 Fellows of The Australian Academy of Science. They join 18 other researchers and scientists this year, nominated by peers for their…
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Posted: 29 May 2023 Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in…
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Posted: 29 May 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed…
PAT-DX1 draft GLP toxicology reports received
Posted: 29 May 2023 Patrys Limited, a therapeutic antibody development company, is pleased to announce that it has received favourable draft reports for two recently completed Good Laboratory Practice (GLP) toxicology studies testing PAT-DX1 in rats and a…
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
Posted: 29 May 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new encouraging clinical data in 1st line non-small cell lung cancer from INSIGHT-003, an investigator-initiated Phase I…
Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership
Posted: 29 May 2023 Ginkgo’s ongoing partnership with Centrient focuses on improving the sustainability of fermentation and enzymatic syntheses of beta-lactam antibiotic APIs. In the first phase of this project, Ginkgo delivered an enzyme with significantly improved efficiency,…
Melbourne Genomics unveils ‘Genomical’ platform: Your launchpad for genomic medicine
Posted: 26 May 2023 GenoVic – the main platform used for clinical genomic testing in Victoria – will now become Genomical and expand its user base across Australia. The platform was released in 2019 to enable multiple laboratories…
Cyteph secures vital funding for brain cancer immunotherapy phase 1 clinical trial
Posted: 26 May 2023 Cyteph, a spin-out biotechnology company from QIMR Berghofer Medical Research Institute, was last night awarded a $1.5m grant via the CUREator incubator. This grant signals an official launch milestone for the Company, supporting its…
